Rabies Human Clinical Trial
Official title:
Randomized, Blind, Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (Vero Cell) Inoculated in 4-dose Program (2-1-1)
A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)
It is to prove that the freeze-dried human rabies vaccine (Vero cell) in the population aged 10-60 years, the four dose vaccination program is not inferior to the five dose vaccination program, and the saftyćantibody positive conversion rate and geometric mean concentration of the four dose group of the test vaccine are not inferior to the five dose program group 14 days after the first dose vaccination. To compare the immunogenicity of people aged 10-60 years old who were vaccinated 6 and 12 months after the whole vaccination, so as to evaluate the antibody positive rate and GMT 6 and 12 months after the test vaccine was vaccinated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06177249 -
To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)
|
Phase 3 | |
| Enrolling by invitation |
NCT05545371 -
Prevention of Rabies With Four Doses of Rabies Vaccine
|
Phase 3 | |
| Completed |
NCT03557008 -
Responses to Rabies Vaccine in Adults With or Without Antibiotics
|
Phase 4 | |
| Completed |
NCT04495569 -
A Bridging Study of the SYN023 on Healthy Adult Subjects
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05382650 -
Survey of Human Rabies Immune Globulin Safety in Children
|
||
| Completed |
NCT04213950 -
Improving Adherence to Rabies PEP Guideline Recommendations
|
N/A |